Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 04.02.16 in Vol 5, No 1 (2016): Jan-Mar

This paper is in the following e-collection/theme issue:

Works citing "Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.4473):

(note that this is only a small subset of citations)

  1. Ness N, Haase R, Kern R, Schriefer D, Ettle B, Cornelissen C, Akguen K, Ziemssen T. The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study. Journal of Medical Internet Research 2020;22(3):e17921
  2. Ness N, Schriefer D, Haase R, Ettle B, Cornelissen C, Ziemssen T. Differentiating societal costs of disability worsening in multiple sclerosis. Journal of Neurology 2020;267(4):1035
  3. D'Amico E, Haase R, Ziemssen T. Review: Patient-reported outcomes in multiple sclerosis care. Multiple Sclerosis and Related Disorders 2019;33:61
  4. Alsop J, Medin J, Cornelissen C, Vormfelde SV, Ziemssen T, Ramagopalan SV. Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. PLOS ONE 2017;12(5):e0173353
  5. Ziemssen T, Hillert J, Butzkueven H. The importance of collecting structured clinical information on multiple sclerosis. BMC Medicine 2016;14(1)